PeptiDream Inc.
PeptiDream Announces Achievement of Development Milestone in Collaboration with MSD
Earlier from Peptidream
- Consolidated Financial Results for the Six Months Ended June 30, 2026 [IFRS]
- Initiation of Phase 1 Clinical Trial by Novartis Marks Milestone for PeptiDream
- PeptiDream Strengthens Leadership Team with Multiple Key Executive Appointments
- PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer